Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of OSAG 101 (Theraloc, nimotuzumab) with Radiotherapy in Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children and Adolescents
2005-003100-11Phase 3Completed
- Sponsor
- Oncoscience AG
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of nimotuzumab in diffuse intrinsic pontine glioma (DIPG), sponsored by Oncoscience AG. Primary endpoint: median progression-free survival time. Started Nov 2005; status: completed.
02
Drugs
nimotuzumab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on 2005-003100-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003100-11.